In a strategic move to tackle severe blood cancers, Alanis Therapeutics (ATI) has teamed up with KBI Biopharma to enhance the development and manufacturing of ATI's preclinical antibody candidate, ATI-D1. This partnership aims to accelerate the treatment of myelodysplastic syndromes (MDS) and acute
The ability to control matter at the atomic level with remarkable precision has long been a dream in the field of nanotechnology. Recent advancements led by physicists at the University of Bath, in collaboration with an international team, have brought us closer to this goal. This breakthrough
In a groundbreaking move aiming to reshape the process of diagnosing colorectal cancer, the Community Diagnostic Centre (CDC) in Telford has launched a £1 million research study known as TRIOMIC. This innovative study is designed to significantly shorten the anxiety-inducing waiting period for a
Recent advancements in synthetic biology have opened new avenues for addressing antimicrobial resistance (AMR), a pressing global health threat. Synthetic biology encompasses the design and engineering of new or modified living systems to combat drug-resistant bacteria effectively. This field
Amgen's obesity drug candidate, MariTide (maridebart cafraglutide, formerly AMG 133), has brought forward promising results in a Phase II clinical trial, sparking hope for a new and effective treatment for obesity. With its innovative design and impressive efficacy, MariTide is positioned as a
Triple-negative breast cancer (TNBC) is a particularly aggressive form of breast cancer, accounting for 15-20% of all breast cancer cases. Known for its poor prognosis and lack of effective treatment options, TNBC presents a significant challenge in oncology. However, recent advancements in spatial
